z-logo
Premium
Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?
Author(s) -
Alexandraki Krystallenia I.,
Nikolaou Argiro,
Thomas Dimitrios,
Syriou Vassiliki,
Korkolopoulou Penelope,
Sougioultzis Stavros,
Kaltsas Gregory
Publication year - 2014
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12346
Subject(s) - autoimmune gastritis , medicine , autoimmune disease , gastritis , chromogranin a , gastrin , hyperplasia , atrophic gastritis , thyroiditis , gastroenterology , autoimmune thyroiditis , thyroid , hashimoto disease , helicobacter pylori , thyroid disease , pathology , disease , immunohistochemistry , secretion
Summary Objective The aim of this study was to investigate the prevalence of autoimmune gastritis, enterochromaffin‐like cell ( ECL ‐cell) hyperplasia and gastric neuroendocrine neoplasms type 1 ( GNEN 1) in patients with autoimmune thyroid disease. Design Prospective observational study in a single institutional study. Patients and Measurements One hundred and twenty patients with autoimmune thyroid disease were consecutively recruited from the E ndocrine U nit. Upper gastrointestinal tract endoscopy ( UGE ) and biochemical parameters for autoimmune thyroid disease and autoimmune gastritis were assessed at recruitment and annually thereafter in patients with a mean follow‐up of 37·5 ± 14·4 months. Autoimmune gastritis was defined by the presence of antiparietal cell antibodies ( APCA ) and histological confirmation after UGE . Serum gastrin and chromogranin Α were also measured. Results One hundred and eleven patients had Hashimoto's thyroiditis and nine G raves' disease. Autoimmune gastritis was identified in 40 (38 with H ashimoto's thyroiditis and two with G raves' disease) patients all of whom had increased levels of gastrin and chromogranin Α ; H elicobacter pylori infection was histologically identified in 15 of 40 (37·5%) patients. Six patients had isolated nodular ECL ‐cell hyperplasia and one mixed nodular and linear ECL ‐cell hyperplasia [7 of 40 (17·5%)]. Only increased gastrin ( P  = 0·03) levels predicted the presence ECL ‐cell hyperplasia. A GNEN 1 developed in one patient with nodular ECL ‐cell hyperplasia after 39 months of follow‐up. Conclusions Concomitant autoimmune gastritis was found in 33·3% of patients with autoimmune thyroid disease, 17·5% of whom had ECL ‐cell hyperplasia that evolved to GNEN 1 in one (2·5%). Larger studies with longer follow‐up are needed to define the incidence of GNEN 1 in patients with autoimmune thyroid disease and ECL ‐cell hyperplasia and potential implications.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom